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Abstract
Presented herein is an examination of the genetic factors related to progression of type 2 diabetic
nephropathy in Japanese patients. Epidemiological evidence strongly suggests that genetic
susceptibility has a major role in the development of nephropathy in patients with type 2 diabetes.
It was found that the DD genotype of angiotensin converting enzyme polymorphism is associated
with progression of Japanese type 2 diabetic nephropathy. Genetic analysis of the corresponding
chromosomal regions in humans, and examination of candidate genes residing at the loci, may
provide a more thorough understanding of genetic factors involved in human type 2 diabetes.
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R E V I E W
A R T I C L E
INTRODUCTION
Diabetic nephropathy is a major complication of type
2 diabetes mellitus and is the most important cause of
end-stage renal failure (ESRF) in Japan. Poor blood
glucose and/or blood pressure control may have an
important role in the initiation and development of
diabetic nephropathy. Diabetic nephropathy is
observed in up to 30% of patients who have type 2
diabetes mellitus for more than 10 years (1-3). Over
the last decade, it has been shown that diabetic
nephropathy clusters in type 2 diabetic families. In
Pima Indians, proteinuria was found to occur in 14%
of diabetic offspring if neither diabetic parent had
proteinuria. The incidence increased to 23% if one
diabetic parent had proteinuria, and to 46% if both
diabetic parents had proteinuria (4).  Familial
clustering of ESRF in African-Americans was reported
by Freedman et al (5,6). Among patients with type 2
diabetes mellitus and ESRF, 37% reported having a
close relative with ESRF. Among age- and sex-
matched type 2 diabetic cases without nephropathy, only
7% reported ESRF in a close relative. In 2001, more
than 30% of Japanese patients who were newly accepted
for regular dialysis had diabetic nephropathy (total
number, 12 186) (3). Familial aggregation of diabetic
nephropathy has been noted both in Pima Indians (4)
and Caucasians (7). Because diabetic nephropathy occurs
in familial clusters and not all patients with poor
metabolic control develop nephropathy, genetic factors
may contribute to susceptibility to this disease. Although
many candidate genes in patients with diabetic
nephropathy have been analyzed, the candidate genes
related to initiation and progression are still obscure in
patients with type 2 diabetic nephropathy.
The purpose of this review is to report our work on the
genetic factors related to progression of type 2 diabetic
nephropathy in Japanese patients.
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only a key regulator of sodium homeostasis, but also a
modulator of vascular tone and possibly vascular structure
(10). Angiotensin II production results in cell growth and
matrix production in the glomeruli and interstitium.
Angiotensin II is released from angiotensinogen (AGT)
by the sequential action of renin and angiotensin
converting enzyme (ACE). The renin-angiotensin system
is generally considered to have an important role in the
development of diabetic nephropathy. Ten poly-
morphisms in the AGT gene were reported by Jeunemaitre
et al (11). Among them, the M235T (methionine to
threonine substitution at codon 235) polymorphism and
the –G6A (G to A substitution at a position 6 base pairs
upstream from the transcription starting site) were in
complete linkage disequilibrium in French and Japanese
populations (11). Inoue et al (12) reported that
substitution of A to G at position –6 increases the basal
transcription rate of the AGT gene in COS-1 cells. The
increased transcription rate suggested that the A-T
haplotype has higher levels of AGT in the serum and
tissues and results in an increased availability of substrate
for the formation of angiotensin II. Studies have shown
that ACE activity is increased not only in sera but also in
renal tissues in diabetic rats (13). A variant form of the
ACE gene, involving intronic insertion/deletion (I/D) of
a 287-base pair Alu sequence, is associated with
increased plasma and tissue activity of this enzyme.
Serum ACE levels are highest in patients with the DD
genotype, lowest in patients with the II genotype, and
intermediate in those with the ID genotype. There are
two isoforms in angiotensin II receptors; one is
angiotensin II receptor type 1 (AT1R) and the other is
the angiotensin II type 2 receptor. The biological effect
of angiotensin II in the kidney is assumed to be expressed
through AT1R. Moczulski et al (14) reported that AT1R
may not be implicated in the etiology of type 1 diabetic
nephropathy.
Three genes, AGT, ACE, and AT1R, were thoroughly
investigated in Japanese populations using case-control
studies (Table 1). In 1999, the authors determined the
relationship between the gene polymorphism of AGT,
GENETIC APPROACH TO TYPE 2
DIABETIC NEPHROPATHY
Two different strategies are available in a search for genes
responsible for susceptibility to diabetic nephropathy.
The first strategy is a genome-wide screening using type
2 diabetic sibling (sib) pairs concordant or discordant
for nephropathy. This method can determine the
chromosomal location responsible for diabetic
nephropathy, but it is difficult to identify a specific gene.
The second strategy is a candidate gene approach for
diabetic nephropathy using a case-control study and the
transmission disequilibrium test (8). There are some
advantages in the case-control study compared with the
sib pairs analysis. Collection of DNA samples, finding a
disease allele, and testing its contribution to the
development of diabetic nephropathy are easier in case-
control studies than in sib pairs analysis. However,
positive findings in a case-control study might be
attributable to unrecognized factors in the population
studies (population stratification). The transmission
disequilibrium test is a very good method for avoiding
this effect. In the transmission disequilibrium test,
affected and non-affected individuals and their parents
(case and control trios) are collected. The gene verified
in the case-control comparison is genotyped in trios and,
using only parents who are heterozygotes for the allele,
transmission of the allele to affected and unaffected
offspring is determined. A transmission frequency of
more than 50% to the affected offspring suggests that
the specific allele increases disease susceptibility. In type
2 diabetic patients, collecting living parents is very
difficult but new study designs have been proposed to
examine allelic associations relying on examination of
affected and unaffected siblings (9).
CASE-CONTROL STUDY IN
JAPANESE WITH TYPE 2
DIABETIC NEPHROPATHY
Renin-angiotensin system
The renin-angiotensin system, which has a central role
in blood pressure regulation and renal function, is not
Study Results
Tomino et al (15) DD genotype in the ACE gene and C allele in the AT1R gene were associated with declining renal function
Yoshida et al (16) DD genotype in the ACE genotype was associated with declining renal function
Oue et al (17) DD genotype in the ACE gene was associated with the progression of microalbuminuria
Kuramoto et al (18) Frequency of D allele in the ACE gene was higher among nephropathy patients with insulin resistance
Ohno et al (19) D allele in the ACE gene was frequent among patients with microalbuminuria and proteinuria
Doi et al (20) D allele in the ACE gene was associated with albuminuria
Fujisawa et al (21) No association with the development of nephropathy
Nakajima et al (22) No association with the development of nephropathy
Mizuiri et al (23) Diabetic patients with II genotype in the ACE gene have a decreased risk for the development of diabetic nephropathy
Reproduced with the kind permission of the publisher from Tomino (18).
Table 1. Genes encoding the renin-angiotensin system.
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Recently, the authors re-evaluated the I/D polymorphism
of the ACE gene in our multicenter trial of ethnically
homogeneous Japanese patients (16,24). The frequency
of the DD genotype (19.7%) was slightly higher in the
advanced and end stages (overt albuminuric patients with
s-Cr levels of less than 1.2 mg/dL, overt albuminuric
patients with s-Cr levels of more than 1.3 mg/dL, but
excluding hemodialysis patients). The frequency of the
DD genotype in the mild stage (normoalbuminuric and
microalbuminuric patients) was 11.2%. The presence of
the DD genotype increased the risk of ESRF more than
that of the other genotypes. It seems that the DD genotype
is associated with progression of Japanese type 2 diabetic
nephropathy. This possibility now needs to be confirmed
by prospective multicenter trials. Furthermore, the effects
of other candidate genes or acquired factors should be
examined in these patients.
Other candidate genes
Many candidate genes for diabetic nephropathy have
been determined using case-control studies in Japanese
populations (Table 3) (25). Endothelial nitric oxide
ACE, or AT1R and the progression of diabetic
nephropathy in a multicenter trial of ethnically
homogeneous Japanese patients with type 2 diabetes (15).
Gene polymorphism of ACE I/D, AGT M235T, and
AT1R A1166C was determined by polymerase chain
amplification using allele-specific primers. Japanese type
2 diabetic patients, 1152 in total, were selected from
several clinics. All patients were divided into three groups
as follows: 1.  normoalbuminuric patients;  2.
microalbuminuric patients; and 3. overt albuminuric
patients. Clinical factors for investigation of all patients
were date of birth, sex, levels of urinary albumin, findings
of the ocular fundus, duration of diabetes, hemoglobin
A1c, and blood pressure. The date when serum creatinine
(s-Cr) was more than 2 mg/dL or when patients had their
first dialysis (hemodialysis or continuous ambulatory
peritoneal dialysis) was obtained. The date was defined
as a primary endpoint. There were no significant
differences in the frequencies of AGT, ACE, or AT1R
p o l y m o r p h i s m  a m o n g  n o r m o a l b u m i n u r i c ,
microalbuminuric, and overt albuminuric patients. There
was no significant relationship between the time to the
primary endpoint and AGT M235T genotype in all
diabetic patients. Yoshida et al (16) also reported that
M235T polymorphism in the AGT gene was not
associated with either the development or progression
of diabetic nephropathy in Japanese type 2 diabetes. Time
to reach the primary endpoint in all diabetic patients who
had the DD genotype was significantly shorter than that
in those who had the II or ID genotype. Especially in the
overt albuminuric patients, the time to reach the primary
endpoint in patients who had the DD genotype was
significantly shorter than that in those who had the II or
ID genotype (Fig. 1) (15). Yoshida et al (16) reported
that AT1R polymorphism was not associated with the
development and progression of diabetic nephropathy.
The authors showed that the C1166 allele in the AT1R
gene was associated with the progression of nephropathy,
particularly in women, but it is unclear whether this allele
has a biological role (Table 2).
Diabetic nephropathy
Male + female Male Female
ACE
   DD/II 1.78* 1.57 1.04
   DD/ID 2.39† 2.32† 2.32
AGT
   MT + MM/TT 0.91 0.96 0.83
AT1R
  AC + CC/AA 1.18 1.36 2.84*
Reproduced with the kind permission of the publisher from Tomino et al (15).
*p<0.025.
†p<0.001.
Table 2. Relative risk using a proportional-hazard regression analysis in patients with diabetic nephropathy.
Figure 1. Relationship between time to reach the primary endpoint
and ACE gene polymorphism in the overt albuminuric group (group
III). Reproduced with the kind permission of the publisher from
Tomino et al (15).
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synthethase is a key enzyme of the endogenous
vasodilator that is essential for the regulation of blood
flow and blood pressure. Methylenetetrahydrofolate
reductase is a key enzyme that is involved in the re-
methylation of homocysteine to methionine. A 4/5-
guanine tract polymorphism in the promoter region of
the plasminogen activator inhibitor-1 gene is related to
the serum levels of plasminogen activator inhibitor-1.
Apolipoprotein E is a 299-amino acid glycoprotein that
has a central role in lipid metabolism. The Trp64Arg
polymorphism of the β3-adrenergic receptor is considered
to be associated with some forms of obesity and insulin
resistance. Aldose reductase 2, a key enzyme of the
polyol pathway, catalyzes nicotinamide adenine
dinucleotide phosphate-dependent reduction of glucose
to sorbitol. An excess accumulation of intracellular
sorbitol has been proposed as an important factor for the
pathogenesis of diabetic microangiopathy. Other
candidate genes such as CCR5, MMP-9, and GSTM1
were also examined in Japan. However, the results of
these candidate genes on the progression of diabetic
nephropathy are controversial. The relationship between
the presence and/or frequency of these candidate genes
and the progression of diabetic nephropathy should be
examined in the future.
CONCLUSION
Epidemiological evidence strongly suggests that genetic
susceptibility has a major role in the development of
nephropathy in patients with type 2 diabetes. It is
concluded that the DD genotype of ACE polymorphism
is associated with progression of Japanese type 2 diabetic
nephropathy. Genetic analysis of the corresponding
chromosomal regions in humans, and examination of
candidate genes residing at the loci, may provide a more
Gene Study Results
eNOS Neugebauer et al (26) Deletion allele in intron 4 was associated with the development of nephropathy
Fujita et al (27) No association with nephropathy
MTHFR Fujita et al (28) No association with nephropathy
Odawara et al (29) No association with nephropathy
Neugebauer et al (30) TT genotype was associated with nephropathy
PAI-1 Kimura et al (31) No association with the progression of nephropathy
ApoE Kimura et al (32) ε4 Allele was protective against the progression of nephropathy
Eto et al (33) Frequency of ε2 allele was higher in patients with nephropathy
β3-AR Sakane et al (34) Homozygotes for Arg64 allele were associated with nephropathy
Nakajima and Baba (35) No association with nephropathy
ALR2 Ichikawa et al (36) No association with nephropathy
Maeda et al (37)
No association with nephropathy
Reproduced with the kind permission of the publisher from Tomino (25).
eNOS = endothelial nitric oxide synthase; MTHFR = methylenetetrahydrofolate reductase; PAI = plasminogen activator inhibitor; ApoE =
Apolipoprotein E; AR = adrenergic receptor; ALR = aldose reductase.
Table 3. Other candidate genes.
thorough understanding of genetic factors involved in
human type 2 diabetes. It is expected that genetic studies
in this field will make dramatic progress using clinical
data and technology.
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